ARTICLE | Emerging Company Profile
Lifordi: Applying ADCs to autoimmune conditions
With $70M series A, biotech backed by Arch, 5am and Atlas is developing a targeted steroid it believes will be safer, with lower and less frequent dosing
February 25, 2025 11:39 PM UTC
Lifordi is making antibody-drug conjugates that deliver steroids or nucleic acids specifically to immune cells in hopes of reducing systemic toxicity of treatments for patients with autoimmune and inflammatory diseases.
Lifordi Immunotherapeutics Inc.’s first program is an antibody-drug conjugate (ADC) targeting VISTA, an immunoregulatory molecule expressed highly and selectively on myeloid and lymphoid cell lineages, for targeted delivery of steroids...
BCIQ Company Profiles
BCIQ Target Profiles
V-region immunoglobulin-containing suppressor of T cell activation (VISTA)